Literature DB >> 15026517

Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation.

M Inglese1, G L Mancardi, E Pagani, M A Rocca, A Murialdo, R Saccardi, G Comi, M Filippi.   

Abstract

To assess whether brain tissue loss occurs after profound and sustained suppression of magnetic resonance imaging (MRI) enhancement, we measured brain volume changes from 10 patients with rapidly evolving secondary progressive multiple sclerosis (MS) treated with autologous haematopoietic stem cell transplantation and followed up for 24 months. An average yearly decrease of brain volume of about 1.9% was observed despite only five enhancing lesions seen on triple dose follow up scans of two patients. This indicates that, in MS, progressive loss of tissue can occur independently of concomitant MRI-visible inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026517      PMCID: PMC1738998     

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  22 in total

Review 1.  Effects of dissolucytotic gold ions on recovering brain lesions.

Authors:  Gorm Danscher; Agnete Larsen
Journal:  Histochem Cell Biol       Date:  2010-03-17       Impact factor: 4.304

2.  Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.

Authors:  Amer Awad; Olaf Stüve
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

3.  Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE.

Authors:  Chunhe Wang; Bruce G Gold; Laurie J Kaler; Xiaolin Yu; Michael E Afentoulis; Gregory G Burrows; Arthur A Vandenbark; Dennis N Bourdette; Halina Offner
Journal:  J Neurochem       Date:  2006-08-03       Impact factor: 5.372

4.  Normal appearing white matter permeability: a marker of inflammation and information processing speed deficit among relapsing remitting multiple sclerosis patients.

Authors:  Eldar Eftekhari; Seyed-Parsa Hojjat; Rita Vitorino; Timothy J Carroll; Charles Grady Cantrell; Liesly Lee; Matthew W Taylor; Sarah A Morrow; Haddas Benhabib; Richard I Aviv; Andrea Kassner
Journal:  Neuroradiology       Date:  2017-06-16       Impact factor: 2.804

Review 5.  Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis.

Authors:  Wolfgang Brück
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

Review 6.  MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.

Authors:  Massimo Filippi; Maria Assunta Rocca
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

Review 7.  Will the real multiple sclerosis please stand up?

Authors:  Peter K Stys; Gerald W Zamponi; Jan van Minnen; Jeroen J G Geurts
Journal:  Nat Rev Neurosci       Date:  2012-06-20       Impact factor: 34.870

Review 8.  Targeting progressive neuroaxonal injury: lessons from multiple sclerosis.

Authors:  Amit Bar-Or; Peter Rieckmann; Anthony Traboulsee; V Wee Yong
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

Review 9.  Emerging therapies for multiple sclerosis.

Authors:  Paolo A Muraro; Bibiana Bielekova
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

10.  A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis.

Authors:  M A Rocca; T Mondria; P Valsasina; M P Sormani; Z H Flach; P A Te Boekhorst; G Comi; R Q Hintzen; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2007-09-20       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.